Skip to main content

SYSTEMATIC REVIEW article

Front. Cardiovasc. Med.
Sec. Heart Failure and Transplantation
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1379257

IGF-1 levels in General Population, Heart Failure and Acromegaly, Differences and projections: Dual Perspectives from Meta-analyses

Provisionally accepted
Yan Hu Yan Hu Yinling Jiang Yinling Jiang Lixia Duan Lixia Duan Songwei Yang Songwei Yang Subinur Tuniyazi Subinur Tuniyazi Jianghua Zou Jianghua Zou Rui Ma Rui Ma Gulina Muhemaitibieke Gulina Muhemaitibieke Xiayidanguli Amuti Xiayidanguli Amuti Yan Ying Guo Yan Ying Guo *
  • People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China

The final, formatted version of the article will be published soon.

    The complex relationship between insulin-like growth factor 1 (IGF-1) levels and heart failure (HF) is not fully understood, particularly across different populations and conditions. This meta-analysis aims to elucidate the dual perspectives of IGF-1 levels in the general population, HF patients, and individuals with treatment-naïve acromegaly, highlighting IGF-1 as a biomarker and potential therapeutic target in HF management.Methods: Studies were searched across multiple electronic databases up to January 2024, and identified independently by reviewers. Outcomes were analysed using Revman 5.4 and STATA 15.Results: A total of 25 articles were ultimately included in the analysis. Six studies compared IGF-1 levels between HF patients and non-HF controls, revealing significantly lower IGF-1 levels in HF patients (mean difference (MD) -20.93 [95% CI -37.88, -3.97] P=0.02). This reduction was consistent across various HF subtypes and severities. Additionally, individuals with intermediate IGF-1 levels had a lower risk of developing HF (risk ratio (RR) 0.78 [95% CI 0.74, 0.83] p<0.01) and HF-related mortality (RR 0.98 [95% CI 0.97, 0.99] p<0.01) compared to those with low IGF-1 levels, suggesting a protective role for maintaining adequate IGF-1 levels. Conversely, treatmentnaïve acromegaly patients, characterized by excessively high IGF-1 levels, showed a significantly higher incidence of both diastolic HF (odds ratio (OR) 9.08 [95% CI 6.20, 13.29] p<0.01), and systolic HF (OR 13.1 [95% CI 6.64,25.84] p<0.01), implicating supraphysiological IGF-1 levels in adverse cardiac outcomes.Our meta-analysis underscores the complex interplay between IGF-1 levels and HF. We found that reduced IGF-1 levels are commonly observed in HF patients and are associated with an increased risk of HF and higher HF-related mortality. Conversely, excessively high levels, as seen in acromegaly, are linked to a higher incidence of HF. Given these results, it is recommended that cardiac function be closely monitored in patients with reduced IGF-1 levels and in patients with acromegaly. These findings suggest that IGF-1 has potential prognostic value for risk stratification in HF.

    Keywords: Insulin-like growth factor 1, Heart Failure, Acromegaly, Hormonal, meta-analyses

    Received: 31 Jan 2024; Accepted: 16 Oct 2024.

    Copyright: © 2024 Hu, Jiang, Duan, Yang, Tuniyazi, Zou, Ma, Muhemaitibieke, Amuti and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yan Ying Guo, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.